Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Accounts Payables (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Accounts Payables readings, the most recent being $443000.0 for Q4 2025.

  • Quarterly Accounts Payables fell 91.38% to $443000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $443000.0 through Dec 2025, down 91.38% year-over-year, with the annual reading at $443000.0 for FY2025, 91.38% down from the prior year.
  • Accounts Payables hit $443000.0 in Q4 2025 for Oramed Pharmaceuticals, down from $560000.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $5.3 million in Q1 2025 and bottomed at $443000.0 in Q4 2025.
  • Average Accounts Payables over 5 years is $3.0 million, with a median of $3.4 million recorded in 2022.
  • The largest annual shift saw Accounts Payables soared 832.85% in 2024 before it plummeted 91.38% in 2025.
  • Oramed Pharmaceuticals' Accounts Payables stood at $4.8 million in 2021, then dropped by 12.67% to $4.2 million in 2022, then plummeted by 86.75% to $551000.0 in 2023, then soared by 832.85% to $5.1 million in 2024, then plummeted by 91.38% to $443000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Accounts Payables are $443000.0 (Q4 2025), $560000.0 (Q3 2025), and $2.2 million (Q2 2025).